Inhibikase Therapeutics (IKT) Assets Average (2021 - 2025)
Historic Assets Average for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to $84.2 million.
- Inhibikase Therapeutics' Assets Average rose 117576.45% to $84.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.2 million, marking a year-over-year increase of 117576.45%. This contributed to the annual value of $56.6 million for FY2024, which is 18675.98% up from last year.
- Per Inhibikase Therapeutics' latest filing, its Assets Average stood at $84.2 million for Q3 2025, which was up 117576.45% from $91.6 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Assets Average peaked at $96.4 million during Q1 2025, and registered a low of $6.6 million during Q3 2024.
- Its 5-year average for Assets Average is $37.4 million, with a median of $30.5 million in 2021.
- Its Assets Average has fluctuated over the past 5 years, first tumbled by 6717.8% in 2024, then skyrocketed by 117576.45% in 2025.
- Inhibikase Therapeutics' Assets Average (Quarter) stood at $44.2 million in 2021, then crashed by 39.42% to $26.8 million in 2022, then plummeted by 39.48% to $16.2 million in 2023, then soared by 217.95% to $51.5 million in 2024, then soared by 63.58% to $84.2 million in 2025.
- Its Assets Average stands at $84.2 million for Q3 2025, versus $91.6 million for Q2 2025 and $96.4 million for Q1 2025.